Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Vismodegib basal cell carcinoma not applicable detail...
SMO D473G Vismodegib basal cell carcinoma resistant detail...
SMO W281C Vismodegib basal cell carcinoma resistant detail...
SMO H231R Vismodegib basal cell carcinoma resistant detail...
SMO Q477E Vismodegib basal cell carcinoma resistant detail...
Unknown unknown Sonidegib basal cell carcinoma not applicable detail...
SMO W535L Sonidegib basal cell carcinoma predicted - sensitive detail...
SMO Q477E Sonidegib basal cell carcinoma no benefit detail...
SMO D473H Sonidegib basal cell carcinoma resistant detail...
SMO D473G Sonidegib basal cell carcinoma resistant detail...
SMO S533N Sonidegib basal cell carcinoma resistant detail...
Unknown unknown Taladegib basal cell carcinoma not applicable detail...
SMO V321M Vismodegib basal cell carcinoma predicted - resistant detail...
SMO W281L Vismodegib basal cell carcinoma predicted - resistant detail...
SMO D473Y Vismodegib basal cell carcinoma predicted - resistant detail...
SMO G497W Vismodegib basal cell carcinoma predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01367665 Phase II Vismodegib STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Completed
NCT01543581 Phase II Vismodegib Vismodegib for Treatment of Basal Cell Carcinoma (Erivedge) Completed
NCT01700049 Phase II Vismodegib Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes Completed
NCT01815840 Phase II Vismodegib A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas Completed
NCT01898598 Phase II Vismodegib A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma Terminated
NCT02067104 Phase II Vismodegib Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention Terminated
NCT02120677 Phase I Itraconazole Topical Itraconazole in the Treatment of Basal Cell Carcinoma Completed
NCT02303041 Phase I Buparlisib + Sonidegib Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Terminated
NCT02436408 FDA approved Vismodegib VISmodegib for ORbital and Periocular Basal Cell Carcinoma Active, not recruiting
NCT02639117 Phase I Vismodegib Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas Completed
NCT02690948 Phase II Pembrolizumab + Vismodegib Pembrolizumab Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Completed
NCT02699723 Phase I Arsenic trioxide + Itraconazole Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer Not yet recruiting
NCT02735356 Phase I Itraconazole Topical Itraconazole in Treating Patients With Basal Cell Cancer Completed
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting
NCT03132636 Phase II Cemiplimab PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy Active, not recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03521830 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Recruiting
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Recruiting
NCT03816332 Phase I Ipilimumab + Nivolumab + Prednisone + Tacrolimus Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Recruiting
NCT03897036 Phase I Silmitasertib Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) Recruiting
NCT04155190 Phase II Patidegib topical gel An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC Recruiting
NCT04323202 Phase I Pembrolizumab Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N Recruiting